SAN RAMON, Calif., February 5, 2020—The U.S. Food and Drug Administration (FDA) has granted CooperVision, Inc. approval for its new Biofinity® toric multifocal contact lenses.
The highly-anticipated product combines the proven optical designs of CooperVision’s Biofinity® toric—the most prescribed toric lens on the market1—and Biofinity® multifocal to provide patients with both the astigmatism and presbyopia vision correction they deserve. The company plans to make the lenses available to U.S. eye care professionals later this year, followed by other markets.
“Biofinity® toric multifocal extends the reliable performance of our Biofinity® toric lenses to presbyopic patients,” said Michele Andrews, OD, Senior Director, Professional and Academic Affairs, North America, CooperVision “U.S. eye care professionals will soon have an easy-to-fit, familiar lens design they can count on to keep current toric wearers satisfied in contact lenses for longer, and provide new astigmatic wearers an alternative to reading glasses. It’s a win-win for practitioners and their patients.”
Lens parameters and other details regarding Biofinity® toric multifocal will be made public in the coming months.
For more information, visit https://coopervision.com/practitioner/only-biofinity-toric-multifocal.
# # #
1 US industry data on file
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of daily disposable, two-week and monthly contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism, presbyopia and childhood myopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies (“Cooper”) is a global medical device company public traded on NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
McDougall Communications for CooperVision, Inc.
firstname.lastname@example.org or +1-585-434-2148